‘It’s Time to Go Back to the Moon.’ Jeff Bezos Unveils Blue Origin’s Lunar Mission
(WASHINGTON) — Amazon tycoon Jeff Bezos says he’s going to send a spaceship to the moon, joining a resurgence of lunar interest half a century after people first set foot there. Bezos says his space company Blue Origin will land a robotic ship the size of a small house, capable of carrying four rovers and using a newly designed rocket engine and souped-up rockets. It would be followed by a version that could bring people to the moon along the same timeframe as NASA’s proposed 2024 return. Bezos, who was dwarfed by his mock-up of the Blue Moon vehicle at his presentation Thursday, says, “This is an incredible vehicle and it’s going to the moon.” Bezos says: “It’s time to go back to the moon. This time to stay.”
Authors: Karimi G, Vard B, Riyahi R, Motlagh ME, Heshmat R, Kelishadi R Abstract This cross-sectional study was conducted among 14,400 Iranian students, aged 7-18 years to determine the association between the frequency of family dinner and mental health. Family dinner frequency, family relationship, life satisfaction (LS), self-perceived health and anxiety were assessed by validated questionnaires. Of 14,274 participants, 50.6% were boys and 71.4% were urban residents, with a mean (SD) age of 12.28 (3.16) years. Family dinner frequency was significantly correlated with LS (boys: β = 0.27, p
In this study we explored the use of a natural compound rubusoside (RUB) as a solubilizer to enhance the solubility of a fluorescence-labeled C6-Ceramide (NBD C6-Ceramide) and to characterize its pharmacokinetics and tissue distribution in an animal model. RUB significantly enhanced the solubility of NBD C6-Ceramide by forming nanomicelles, and efficiently delivered NBD C6-Ceramide in rats by oral and intravenous administration. RUB loaded 1.96% of NBD C6-Ceramide in the nanomicelles and solubilized it to a concentration of 3.6 mg/mL in water. NBD C6-Ceramide in nanomicelles remained stable in aqueous solutions, all...
Publication date: Available online 10 December 2019Source: Prostaglandins &Other Lipid MediatorsAuthor(s): Giorgio Mottola, Evan Werlin, Bian Wu, Mian Chen, Anuran Chatterjee, Melinda Schaller, Michael S. ConteAbstractInflammation ensuing from vascular injury promotes intimal hyperplasia (IH) and restenosis. Resolvin D1 (RvD1) is a lipid mediator that attenuates IH in vivo when delivered locally to the vessel wall in animal models. We tested the hypothesis that peri-procedural oral administration of RvD1 could blunt the local inflammatory response to angioplasty, and attenuate downstream IH. Carotid angioplasty was per...
First-of-its-kind trial evaluates decision aid’s efficacy
Authors: Glauser W PMID: 31818934 [PubMed - in process]
Authors: Owens B PMID: 31818933 [PubMed - in process]
Authors: Dermer M, Martel J, Greenhill A PMID: 31818932 [PubMed - in process]
Authors: Robson R PMID: 31818931 [PubMed - in process]
Authors: Lamb S PMID: 31818930 [PubMed - in process]
Authors: Zimmer V, Glanemann M, Lammert F PMID: 31818929 [PubMed - in process]
More News: Science